Evidence map›Paper›PMID 30252528›Full record

ArticleAmerican journal of public health2018

The Mother of All Pandemics Is 100 Years Old (and Going Strong)!

David M Morens, Jeffery K Taubenberger

Abstract readHistorical Article
In one paragraph

Article in American journal of public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Co-seasonality and co-detection of respiratory viruses and bacteraemia in children: a retrospective analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2020
    Article
  18. Article
  19. The 1918 Influenza Pandemic and Its Legacy.Cold Spring Harbor perspectives in medicine · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David M MorensDavid M. Morens and Jeffery K. Taubenberger are with the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. David M. Morens is Senior Adsvisor to the Director in the Office of the Director, and Jeffery K. Taubenberger is Chief, Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases.
Jeffery K TaubenbergerDavid M. Morens and Jeffery K. Taubenberger are with the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. David M. Morens is Senior Adsvisor to the Director in the Office of the Director, and Jeffery K. Taubenberger is Chief, Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases.

Funding

Influenza Viral PathogenesisZIAAI000986 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TAUBENBERGER, JEFFERY · 2009 to 2025
$30.0M
6 · The paper itself

Abstract

This year marks the 100th anniversary of the deadliest event in human history. In 1918-1919, pandemic influenza appeared nearly simultaneously around the globe and caused extraordinary mortality (an estimated 50-100 million deaths) associated with unexpected clinical and epidemiological features. The descendants of the 1918 virus remain today; as endemic influenza viruses, they cause significant mortality each year. Although the ability to predict influenza pandemics remains no better than it was a century ago, numerous scientific advances provide an important head start in limiting severe disease and death from both current and future influenza viruses: identification and substantial characterization of the natural history and pathogenesis of the 1918 causative virus itself, as well as hundreds of its viral descendants; development of moderately effective vaccines; improved diagnosis and treatment of influenza-associated pneumonia; and effective prevention and control measures. Remaining challenges include development of vaccines eliciting significantly broader protection (against antigenically different influenza viruses) that can prevent or significantly downregulate viral replication; more complete characterization of natural history and pathogenesis emphasizing the protective role of mucosal immunity; and biomarkers of impending influenza-associated pneumonia.

Indexed as

Influenza A Virus, H1N1 SubtypeBiomarkersForecastingGlobal HealthHistory, 20th CenturyHumansImmunity, MucosalInfluenza Pandemic, 1918-1919Influenza VaccinesPneumonia, BacterialUnited StatesBiomarkersInfluenza Vaccines

Identifiers

PMID30252528
PMCPMC6187799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.